The study will look at whether taking clozapine (Clozaril®) once a day is just as good as taking it twice a day by observing participants who are currently taking Clozapine twice daily. Participants will randomly be assigned to either the treatment as usual maintenance group (i.e, taking clozapine twice daily) or the switch group (i.e., taking clozapine once daily).
Eligibility Criteria
- Individuals diagnosed schizophrenia/schizoaffective disorder, receiving clozapine twice daily for 3 months
- Age range: 18+
- Gender: All
- Ethnicity: All
What does the study involve?
- Number of contacts: 6 visits following a screening for eligibility
- Time period: 12 weeks
- Length of contacts: 1-hour visits
- Format of study: In-Person
- Compensation offered? Yes
Investigator(s): Dr. Gary Remington
Full Study Title: Switching from Twice-Daily to Once-Daily Clozapine Dosing in Schizophrenia: A Pilot, Double-Blind, Randomized Controlled Trial
Contact Information:
E-mail: carol.borlido@camh.ca
REB number: 096/2015
REB Approval Expiry Date: October 1, 2026
PLEASE NOTE:
- Research staff cannot give medical advice over the phone or via email.
- If you have specific questions regarding your health care, please contact your family physician.
- We regret that not everyone screened for a study will be eligible to participate
- For more information about other treatment options for mental illness or addiction offered by CAMH, visit www.camh.ca or call 416-535-8501.